Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDNA X Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | $5.04 | $5.04 | $5.04 |
| Q2 2026 | 1 | $5.22 | $5.22 | $5.22 |
| Q3 2026 | 1 | $5.04 | $5.04 | $5.04 |
| Q4 2026 | 1 | $4.86 | $4.86 | $4.86 |
DNA X Inc. Earnings Date And Information
DNA X Inc. last posted its earnings results on Friday, October 31st, 2025. The company reported $-3.86 earnings per share for the quarter, missing analysts' consensus estimates of $5.4 by $9.26. The company had revenue of 16.21 M for the quarter and had revenue of 58.30 M for the year. DNA X Inc. has generated $-7 earnings per share over the last year ($-7.13 diluted earnings per share) and currently has a price-to-earnings ratio of -1.46. DNA X Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
DNA X Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/31/2025 | Q3 2025 | $5.40 | -$4.83 | -10.23 | $34.34 M | $16.21 M |
| 08/08/2025 | Q2 2025 | $0.72 | -$0.79 | -1.51 | $29.17 M | $11.19 M |
| 05/12/2025 | Q1 2025 | -$0.13 | $0.08 | 0.21 | N/A | $16.72 M |
| 03/31/2025 | Q4 2024 | N/A | -$4.41 | N/A | N/A | $14.98 M |
| 11/13/2024 | Q3 2024 | -$0.66 | -$0.52 | 0.14 | $14.78 M | $15.02 M |
| 08/09/2024 | Q2 2024 | -$1.41 | -$1.41 | 0 | $10.91 M | $11.52 M |
| 05/14/2024 | Q1 2024 | -$0.30 | -$0.65 | -0.35 | N/A | $16.78 M |
| 03/27/2024 | Q4 2023 | $0.10 | -$0.31 | -0.41 | N/A | $13.43 M |
| 11/14/2023 | Q3 2023 | $0.01 | $0.12 | 0.11 | N/A | $27.57 M |
| 08/14/2023 | Q2 2023 | N/A | $0.12 | N/A | N/A | $26.84 M |
| 05/08/2023 | Q1 2023 | N/A | $0.06 | N/A | N/A | $25.80 M |
| 03/20/2023 | Q4 2022 | -$1.00 | -$0.25 | 0.75 | N/A | $24.12 M |
| 11/14/2022 | Q3 2022 | -$2.00 | -$0.45 | 1.55 | N/A | $20.50 M |
| 08/12/2022 | Q2 2022 | -$3.00 | -$2.19 | 0.81 | N/A | $11.96 M |
| 05/10/2022 | Q1 2022 | -$0.50 | -$3.77 | -3.27 | N/A | $13.26 M |
| 03/21/2022 | Q4 2021 | -$4.00 | -$7.24 | -3.24 | N/A | $15.93 M |
| 11/10/2021 | Q3 2021 | N/A | -$13.08 | N/A | N/A | $14.45 M |
| 08/16/2021 | Q2 2021 | -$10.00 | -$10.05 | -0.05 | N/A | $11.95 M |
| 05/11/2021 | Q1 2021 | -$10.00 | -$13.99 | -3.99 | N/A | $12.24 M |
| 03/18/2021 | Q4 2020 | N/A | -$9.66 | N/A | N/A | $15.84 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
DNA X Inc. Earnings: FAQ's
The conference call for DNA X Inc.'s latest earnings report can be listened to online.
The conference call transcript for DNA X Inc.'s latest earnings report can be read online.
DNA X Inc. (:SONM) has a recorded annual revenue of $58.30 M.
DNA X Inc. (:SONM) has a recorded net income of $-33,648,000.DNA X Inc. has generated $-7.13 earnings per share over the last four quarters.
DNA X Inc. (:SONM) has a price-to-earnings ratio of -1.46 and price/earnings-to-growth ratio is 0.02.